Ruth L Katz

US Patent:

6797471, Sep 28, 2004

Filed:

Aug 6, 2001

Appl. No.:

09/923304

Inventors:

Ruth Katz - Houston TX
Feng Jiang - Houston TX

Assignee:

Board of Regents, The University of Texas System - Austin TX

International Classification:

C07H 2104

US Classification:

435 6, 536 231

Abstract:

Gene probes for specific regions of chromosome 3 (3p21. 3) and chromosome 10 (10q22) have been found to be tools for the diagnosis and prognosis of smoking related cancers such as non-small cell lung cancer (NSCLC). For example, these probes can be used with fluorescence in situ hybridization (FISH), and used to stratify smokers into high and low risk groups, as well as determine a patients susceptibility to the development of smoking related cancers.

US Patent:

7741034, Jun 22, 2010

Filed:

Sep 28, 2004

Appl. No.:

10/952251

Inventors:

Ruth Katz - Houston TX, US
Feng Jiang - Houston TX, US

Assignee:

Board of Regents, The University of Texas System - Austin TX

International Classification:

C07H 21/04
C12Q 1/68

US Classification:

435 6, 435 911, 435 912, 536 231, 536 243

Abstract:

Gene probes for specific regions of chromosome 3 (3p21. 3) and chromosome 10 (10q22) have been found to be tools for the diagnosis and prognosis of smoking related cancers such as non-small cell lung cancer (NSCLC). For example, these probes can be used with fluorescence in situ hybridization (FISH), and used to stratify smokers into high and low risk groups, as well as determine a patients susceptibility to the development of smoking related cancers.

US Patent:

8093001, Jan 10, 2012

Filed:

Apr 15, 2010

Appl. No.:

12/761134

Inventors:

Ruth Katz - Houston TX, US
Feng Jiang - Houston TX, US

Assignee:

Board of Regents, The University of Texas System - Austin TX

International Classification:

C07H 21/04
C12Q 1/68

US Classification:

435 61, 435 611, 435 614, 435 911, 435 912, 536 231, 536 243

Abstract:

Gene probes for specific regions of chromosome 3 (3p21. 3) and chromosome 10 (10q22) have been found to be tools for the diagnosis and prognosis of smoking related cancers such as non-small cell lung cancer (NSCLC). For example, these probes can be used with fluorescence in situ hybridization (FISH), and used to stratify smokers into high and low risk groups, as well as determine a patients susceptibility to the development of smoking related cancers.

US Patent:

20070218480, Sep 20, 2007

Filed:

Jan 25, 2007

Appl. No.:

11/627253

Inventors:

Ruth Katz - Houston TX, US
Feng Jiang - Ellicott City MD, US

International Classification:

C12Q 1/68

US Classification:

435006000

Abstract:

Gene probes for specific regions of chromosomes 1, 3, 9, 10 and 17 are now shown to be useful in the diagnosis and prognosis of smoking related cancers such as non-small cell lung cancer (NSCLC). For example, these probes can be used with fluorescence in situ hybridization (FISH), and used to stratify smokers into high and low risk groups, to determine susceptibility to the development of smoking related cancers, to predict cancer progression and treatment efficacy, and to rule out other diseases.

US Patent:

20090162839, Jun 25, 2009

Filed:

Aug 31, 2005

Appl. No.:

11/574449

Inventors:

Ruth L. Katz - Houston TX, US
Jun Gu - Houston TX, US
Abha Khanna - Houston TX, US
Ricardo Fernandez - Houston TX, US

Assignee:

Board of Regents, The University of Texas System - Austin TX

International Classification:

C12Q 1/68

US Classification:

435 6

Abstract:

The present invention concerns a quantitative in situ assessment of mean telomere length, particularly in relation to nuclear area, for the diagnosis and/or prognosis of cancer. In particular aspects, the methods and compositions regard diagnosis and/or prognosis of bladder cancer, urothelial cancer, lung cancer, and lymphoma.

US Patent:

20100317002, Dec 16, 2010

Filed:

Oct 6, 2008

Appl. No.:

12/682594

Inventors:

Michal Daniely - Ganei Tikva, IL
Lea Madi - Rishon-LeZion, IL
Tal Kaplan - Gan-Yavne, IL
Boaz Pal - Tel-Aviv, IL
Yuval Harari - D.N. Emek Soreq, IL
Tanweer M. Zaidi - Houston TX, US
Ricardo L. Fernandez - Houston TX, US
Jinping Zhang - Houston TX, US
Ruth Katz - Houston TX, US

Assignee:

Bioview Ltd. - Nes Ziona

International Classification:

C12Q 1/68

US Classification:

435 6

Abstract:

Provided is a method of identifying a genetically abnormal cell in a sputum sample, the method comprising: (a) staining a sputum sample using a morphological stain so as to identify a lower airway tract cell or lung cell in the sputum sample; and (b) staining the sputum sample using fluorescent in situ hybridization (FISH) so as to identify in the lower airway tract cell or lung cell a genetic abnormality in at least one of human chromosome 3p22.1 and 10q22-23, thereby identifying the genetically abnormal cell in the sputum sample. Also provided are methods and kits of diagnosing lung cancer by detecting a presence of genetically abnormal cells above a predetermined threshold in a sputum sample.

US Patent:

20110189670, Aug 4, 2011

Filed:

Jul 7, 2009

Appl. No.:

13/002944

Inventors:

Ruth L Katz - Houston TX, US
Abha Khanna - Sugar Land TX, US
Tanweer M. Zaidi - Missouri City TX, US
Weigong He - Sugar Land TX, US
Ricardo L. Fernandez - Houston TX, US
Ivan Gorlov - Houston TX, US

International Classification:

C12Q 1/68

US Classification:

435 611

Abstract:

The present invention comprises a method of detecting circular tumor cells and methods of detecting, evaluating, or staging cancer in a patient, as well as a method of monitoring treatment of cancer in a patient using the claimed method. The method comprises contacting a sample with a CD45 binding agent; selecting the cells based on positive or negative CD45 staining; contacting the selected cells with a labeled nucleic acid probe, and detecting hybridized cells by fluorescence in situ hybridization; and analyzing a signal produced by the labels on the hybridized cells to detect the CTCs. In other embodiments, the method provides for directed to a method of determining the level of CTCs in a sample having blood cells from a patient by contacting a sample having blood cells from a patient, wherein the sample has not been pre-sorted into CD45-positive and CD45-negative cells.

US Patent:

20120237931, Sep 20, 2012

Filed:

Mar 14, 2012

Appl. No.:

13/420046

Inventors:

RUTH L. KATZ - Houston TX, US

International Classification:

G01N 21/64

US Classification:

435 611

Abstract:

The present invention comprises a method of detecting circular tumor cells and methods of detecting, evaluating, or staging cancer in a patient, as well as a method of monitoring treatment of cancer in a patient using the claimed method. The method comprises contacting a sample with a ALDH1 binding agent; selecting the cells based on positive or negative ALDH1 staining; contacting the selected cells with a labeled nucleic acid probe, and detecting hybridized cells by fluorescence in situ hybridization; and analyzing a signal produced by the labels on the hybridized cells to detect the CTCs. In other embodiments, the method provides for directed to a method of determining the level of CTCs in a sample having blood cells from a patient by contacting a sample having blood cells from a patient, wherein the sample has not been pre-sorted into ALDH1-positive and ALDH1-negative cells.